Impact Assessment of Foetal Haemoglobin on Biochemical Markers of Liver Function in Sickle Cell Disease Patients

Mathias Abiodun Emokpae; Rossy Jane Umeadi

doi:doi:10.11648/j.ajbls.20150303.16

| Peer-Reviewed

Impact Assessment of Foetal Haemoglobin on Biochemical Markers of Liver Function in Sickle Cell Disease Patients

Mathias Abiodun Emokpae, Rossy Jane Umeadi

Published in American Journal of Biomedical and Life Sciences (Volume 3, Issue 3)

Received: 15 April 2015 Accepted: 29 April 2015 Published: 13 May 2015

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background/objective: The role of foetal haemoglobin (HbF) on the modulation of clinical manifestations in sickle cell disease is well known but there is inconsistency as to the levels of HbF that may protective against the development of liver disease. This study evaluates the impact of HbF on biochemical markers of liver function in sickle cell disease (SCD) patients in steady clinical state. Materials and Methods: Liver function tests: aspartate amino transferase, alanine amino transferase, alkaline phosphatase, bilirubin and proteins as well as HbF were assayed in SCD patients using colorimetric methods. Results: Out of 100 SCD patients, 24% had high (>5%) HbF while 76% had low (<4.9%) HbF levels. Those subjects with high HbF had lower (p<0.001) levels of measured variables except albumin which was higher compared to levels in those with low HbF. HbF correlated negatively with the measured variables except albumin. Conclusion: The SCD patients with high HbF had lower levels of the measured variables compared to those with low levels of HbF. High HbF levels (>5%) may be protective against the development of liver pathology in SCD patients in steady clinical state.

Published in	American Journal of Biomedical and Life Sciences (Volume 3, Issue 3)
DOI	10.11648/j.ajbls.20150303.16
Page(s)	61-66
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Foetal Haemoglobin, Liver Disease, Liver Function Tests, Sickle Cell Disease, Steady Clinical State

References

[1]	Steinberg MH, Forget BG, Higgs DR, Weatherall DJ. (2009). Disorders of Hemoglobin: Genetics, Pathophysiology, Clinical Management (2nd ed). Cambridge, United Kingdom: Cambridge University Press. 2009,p 209 – 213.
[2]	Ballas SK. Sickle cell anaemia; progress in pathogenesis and treatment. Drugs 2002; 62(8):1143-1172.
[3]	Boctor FN, Uehlinger J. Malaria and Sickle cell Disease. N Engl J Med 2002; 347(1):35-36.
[4]	Oneal PA, Gantt NM, Schwartz JD, Bhanu NV, Lee YT, Moroney JW et al. Fetal haemoglobin silencing in humans. Blood 2006; 108(6):2081-2086.
[5]	Banerjee S, Owen C,Chopra S. Sickle cell hepatopathy. Hepatology 2001; 33: 1021.
[6]	Berry P, Cross T, Thein S. Hepatic dysfunction in sickle cell disease: a new system of classification based on global assessment. Clin. Gastroenterol Hepatol 2007; 5: 1469.
[7]	Maher MM, Mansour AH. Study of chronic hepatopathy in patients with sickle cell disease. Gastroenterol Res 2009; 2(6):338-343.
[8]	Ebert E, Nagar M, Hagspiel K. Gastrointestinal and hepatic complications of sickle cell disease. Clin Gastroenterol Hepatol 2010;8: 483.
[9]	Sheeley TW. Sickle cell hepatopathy. South Med J 1977;70(5):533-538.
[10]	O’Callaghan A, O’Brien SG, Ninkovic M, Butcher GP, Foster CS, Walters JR, Roberts IA. Chronic intrahepatic cholestasis in sickle cell disease requiring exchange transfusion. Gut 1995;37(1):144-147.
[11]	Gurkan E, Ergun Y, Zorludemir S, Baslamisli F, Kocak R. Liver involvement in sickle cell disease. Turk J Gastroenterol 2005;16(4):194-198.
[12]	Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin CT, Sebastina P et al. Fetal haemoglobin in sickle cell anemia. 2011;118:19-27.
[13]	Atweh GF, Loukopoulos D. Pharmacological induction of fetalhaemoglobin in sickle cell disease and beta-thalassemia. SeminHematol 2001;38(4):367-373.
[14]	Mehta SR, Afenyi-Annan A, Byrns PJ, Lottenberg R. Opportunitiesti improve outcomes in sickle cell disease. Am Fam Physician 2006;74(2):303-310.
[15]	BetkeK,Marti HR, Schlicht I. Estimation of small percentages of foetalhaemoglobin. Nature (Lond), 1959;184:1877-1878.
[16]	Donaldson A, Thomas P, Serjeant BE, Serjeant GR. Foetalhaemoglobin in homozygous sickle cell disease: a study of patients with low HBF levels. Clin Lab Haematol 2001; 23(5):285-289.
[17]	Powars D, Weiss N, Chan S, Schroeder A.. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood. 1984;63(4):921-926.
[18]	Kotila TR, Fawole OI, Shokunbi WA. Haemoglobin F and clinical severity of sickle cell anaemia among Nigerian adults. Afr J Med Sci 2000;29(3-4):229-231.
[19]	Jiya NM, Matazu IK, BilbisLS,Shehu RA. Serum levels of antioxidant vitamins in foetalhaemoglobin (HbF) persistent sickle cell anaemia children in Sokoto, Nigeria. Annals Afr Med 2005;4(4):168-171.
[20]	Adekile A, Huisman T. Level of fetal hemoglobin in children with sickle cell anemia: influence of gender, haplotype and alpha-thalassemia-2 trait. ActaHaematol 1993; 90(1): 34.
[21]	Gladwin M., Schechter A., Coles W., Reiter c. and Ognibene. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation. 2003;107: 271-278.
[22]	Ikuta T, Ausenda S, Cappellini M. Mechanism for fetal globin gene expression: role of the soluble guanylatecyclase-cGMP-depentent protein kinase pathway. Proc. Natl. Acad. Sci. USA. 2001;98:1847-1852.
[23]	Isah I, Udomah F, Erhabor O, Aghedo F, Uko E, Okwubili A. Fetal Haemoglobin levels in SCD patients in Sokoto, Nigeria. Brit. J. Med. Health Sci. 2013;1 (6): 36-47.
[24]	Uko E, Ibeh M, Gwanmesia F. Frequency of foetalhaemoglobin and haemoglobin values in various haemoglobin genotype in Calabar, Nigeria. East Afr. Med. J. 1997;74: 809-811.
[25]	Falusi A, Esan G. Foetalhaemoglobin levels in sickle cell anaemia in Nigeria. Afri J Med MedSci 1989;18:145-149.
[26]	Taiwo K, Kayode A, Aduragbenro A, Olayiwola O, Eyitayo F BiobeleB.Liver dysfunction in steady state sickle cell disease. Annals of Hepatolo. 2005; 4(4): 261-263.
[27]	Nsiah K, Dzogbefia V, Ansong D, Osei AA, Boateng H, Ocloo D. Pattern of AST and ALT changes in relation to hemolysis in sickle cell disease.Clin Med Insight Blood Disord2011;4:1–9.
[28]	Pandey S, Sharma A, Dahia S, Shah V R. Biochemical Indicator of Sickle Cell Disease: Preliminary Report from India. Ind. J. Clin Biochem2012;27(2): 191–195.
[29]	Schubert TT. Hepatobiliary system in Sickle cell disease. Gastroenterology 1986;90(6):2013-2021.
[30]	Molavi MA, Sajjadi HS, Nazemi A, Ghahramani F, Molavi K, Amernia B, Doozandeh H. The determination of hepatic enzymes levels in Children with sickle cell anaemia and correlation with age, gender,HbS and HbF variables. Asian J Med Pharm Res 2012;2(2):43-46.
[31]	Murakami J, Shimuzu Y. Hepatic manifestations in haematological disorders. Int J Hepatol 2013(2013):1-13.
[32]	Adu EM, Okosun RE, Bini EN, Ophori EA. Effects of the sickle cell (s) gene on serum protein profile. Continental J Biomed Sci 2012;6(2):1-5.
[33]	Johnson S, Omata M, Tong J, Simmons F, Weiner J,Tatter D. (1985). Liver involvement in sickle cell disease. Med. (Baltimore)1985;64:349-356.
[34]	IsichieP. Serum proteins profile in sickle cell disease. J. Clin Path 1979; 32: 171-121.
[35]	Adenike A, Bakare R, Fajimi L, OgunyemiO, ObisesanA, SokoyaG.Serum protein levels in sickle cell disease. Afr. J. Med. Pharm. Sci. 1998;1: 40-43.
[36]	Famodu A, Omodiale P, AdedejiO, Reid L. Serum protein study in adult Nigerians with sickle cell anaemia. Med. Sci. Res. 1987;15: 193-194.
[37]	Tripathi S, Dadsena R, Kumar A. Study of Certain Biochemical Parameters in Patients of Sickle Cell Anemia. AdvBiores 2011; 2 (2):79-81.

Cite This Article

Plain Text BibTeX RIS

APA Style

Mathias Abiodun Emokpae, Rossy Jane Umeadi. (2015). Impact Assessment of Foetal Haemoglobin on Biochemical Markers of Liver Function in Sickle Cell Disease Patients. American Journal of Biomedical and Life Sciences, 3(3), 61-66. https://doi.org/10.11648/j.ajbls.20150303.16

Copy | Download

ACS Style

Mathias Abiodun Emokpae; Rossy Jane Umeadi. Impact Assessment of Foetal Haemoglobin on Biochemical Markers of Liver Function in Sickle Cell Disease Patients. Am. J. Biomed. Life Sci. 2015, 3(3), 61-66. doi: 10.11648/j.ajbls.20150303.16

Copy | Download

AMA Style

Mathias Abiodun Emokpae, Rossy Jane Umeadi. Impact Assessment of Foetal Haemoglobin on Biochemical Markers of Liver Function in Sickle Cell Disease Patients. Am J Biomed Life Sci. 2015;3(3):61-66. doi: 10.11648/j.ajbls.20150303.16

Copy | Download

@article{10.11648/j.ajbls.20150303.16,
  author = {Mathias Abiodun Emokpae and Rossy Jane Umeadi},
  title = {Impact Assessment of Foetal Haemoglobin on Biochemical Markers of Liver Function in Sickle Cell Disease Patients},
  journal = {American Journal of Biomedical and Life Sciences},
  volume = {3},
  number = {3},
  pages = {61-66},
  doi = {10.11648/j.ajbls.20150303.16},
  url = {https://doi.org/10.11648/j.ajbls.20150303.16},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20150303.16},
  abstract = {Background/objective: The role of foetal haemoglobin (HbF) on the modulation of clinical manifestations in sickle cell disease is well known but there is inconsistency as to the levels of HbF that may protective against the development of liver disease. This study evaluates the impact of HbF on biochemical markers of liver function in sickle cell disease (SCD) patients in steady clinical state. Materials and Methods: Liver function tests: aspartate amino transferase, alanine amino transferase, alkaline phosphatase, bilirubin and proteins as well as HbF were assayed in SCD patients using colorimetric methods. Results: Out of 100 SCD patients, 24% had high (>5%) HbF while 76% had low (5%) may be protective against the development of liver pathology in SCD patients in steady clinical state.},
 year = {2015}
}

Copy | Download

TY  - JOUR
T1  - Impact Assessment of Foetal Haemoglobin on Biochemical Markers of Liver Function in Sickle Cell Disease Patients
AU  - Mathias Abiodun Emokpae
AU  - Rossy Jane Umeadi
Y1  - 2015/05/13
PY  - 2015
N1  - https://doi.org/10.11648/j.ajbls.20150303.16
DO  - 10.11648/j.ajbls.20150303.16
T2  - American Journal of Biomedical and Life Sciences
JF  - American Journal of Biomedical and Life Sciences
JO  - American Journal of Biomedical and Life Sciences
SP  - 61
EP  - 66
PB  - Science Publishing Group
SN  - 2330-880X
UR  - https://doi.org/10.11648/j.ajbls.20150303.16
AB  - Background/objective: The role of foetal haemoglobin (HbF) on the modulation of clinical manifestations in sickle cell disease is well known but there is inconsistency as to the levels of HbF that may protective against the development of liver disease. This study evaluates the impact of HbF on biochemical markers of liver function in sickle cell disease (SCD) patients in steady clinical state. Materials and Methods: Liver function tests: aspartate amino transferase, alanine amino transferase, alkaline phosphatase, bilirubin and proteins as well as HbF were assayed in SCD patients using colorimetric methods. Results: Out of 100 SCD patients, 24% had high (>5%) HbF while 76% had low (5%) may be protective against the development of liver pathology in SCD patients in steady clinical state.
VL  - 3
IS  - 3
ER  -

Copy | Download

Author Information

Mathias Abiodun Emokpae

Department of Medical Laboratory Science, School of Basic Medical Sciences, College of Medical Sciences, University of Benin, Benin City, Nigeria
Rossy Jane Umeadi

Department of Medical Laboratory Science, School of Basic Medical Sciences, College of Medical Sciences, University of Benin, Benin City, Nigeria

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Mathias Abiodun Emokpae, Rossy Jane Umeadi. (2015). Impact Assessment of Foetal Haemoglobin on Biochemical Markers of Liver Function in Sickle Cell Disease Patients. American Journal of Biomedical and Life Sciences, 3(3), 61-66. https://doi.org/10.11648/j.ajbls.20150303.16

Copy | Download

ACS Style

Mathias Abiodun Emokpae; Rossy Jane Umeadi. Impact Assessment of Foetal Haemoglobin on Biochemical Markers of Liver Function in Sickle Cell Disease Patients. Am. J. Biomed. Life Sci. 2015, 3(3), 61-66. doi: 10.11648/j.ajbls.20150303.16

Copy | Download

AMA Style

Mathias Abiodun Emokpae, Rossy Jane Umeadi. Impact Assessment of Foetal Haemoglobin on Biochemical Markers of Liver Function in Sickle Cell Disease Patients. Am J Biomed Life Sci. 2015;3(3):61-66. doi: 10.11648/j.ajbls.20150303.16

Copy | Download

@article{10.11648/j.ajbls.20150303.16,
  author = {Mathias Abiodun Emokpae and Rossy Jane Umeadi},
  title = {Impact Assessment of Foetal Haemoglobin on Biochemical Markers of Liver Function in Sickle Cell Disease Patients},
  journal = {American Journal of Biomedical and Life Sciences},
  volume = {3},
  number = {3},
  pages = {61-66},
  doi = {10.11648/j.ajbls.20150303.16},
  url = {https://doi.org/10.11648/j.ajbls.20150303.16},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20150303.16},
  abstract = {Background/objective: The role of foetal haemoglobin (HbF) on the modulation of clinical manifestations in sickle cell disease is well known but there is inconsistency as to the levels of HbF that may protective against the development of liver disease. This study evaluates the impact of HbF on biochemical markers of liver function in sickle cell disease (SCD) patients in steady clinical state. Materials and Methods: Liver function tests: aspartate amino transferase, alanine amino transferase, alkaline phosphatase, bilirubin and proteins as well as HbF were assayed in SCD patients using colorimetric methods. Results: Out of 100 SCD patients, 24% had high (>5%) HbF while 76% had low (5%) may be protective against the development of liver pathology in SCD patients in steady clinical state.},
 year = {2015}
}

Copy | Download

TY  - JOUR
T1  - Impact Assessment of Foetal Haemoglobin on Biochemical Markers of Liver Function in Sickle Cell Disease Patients
AU  - Mathias Abiodun Emokpae
AU  - Rossy Jane Umeadi
Y1  - 2015/05/13
PY  - 2015
N1  - https://doi.org/10.11648/j.ajbls.20150303.16
DO  - 10.11648/j.ajbls.20150303.16
T2  - American Journal of Biomedical and Life Sciences
JF  - American Journal of Biomedical and Life Sciences
JO  - American Journal of Biomedical and Life Sciences
SP  - 61
EP  - 66
PB  - Science Publishing Group
SN  - 2330-880X
UR  - https://doi.org/10.11648/j.ajbls.20150303.16
AB  - Background/objective: The role of foetal haemoglobin (HbF) on the modulation of clinical manifestations in sickle cell disease is well known but there is inconsistency as to the levels of HbF that may protective against the development of liver disease. This study evaluates the impact of HbF on biochemical markers of liver function in sickle cell disease (SCD) patients in steady clinical state. Materials and Methods: Liver function tests: aspartate amino transferase, alanine amino transferase, alkaline phosphatase, bilirubin and proteins as well as HbF were assayed in SCD patients using colorimetric methods. Results: Out of 100 SCD patients, 24% had high (>5%) HbF while 76% had low (5%) may be protective against the development of liver pathology in SCD patients in steady clinical state.
VL  - 3
IS  - 3
ER  -

Copy | Download